Cargando…
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
BACKGROUND: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. METHODS: We have analysed the outcomes of 3,187...
Autores principales: | Slavicek, Lubomir, Pavlik, Tomas, Tomasek, Jiri, Bortlicek, Zbynek, Buchler, Tomas, Melichar, Bohuslav, Vyzula, Rostislav, Prausova, Jana, Finek, Jindrich, Majek, Ondrej, Dusek, Ladislav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987650/ https://www.ncbi.nlm.nih.gov/pubmed/24666582 http://dx.doi.org/10.1186/1471-230X-14-53 |
Ejemplares similares
-
Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry
por: Pavlík, Tomáš, et al.
Publicado: (2012) -
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014) -
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015) -
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017) -
Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
por: Buchler, Tomas, et al.
Publicado: (2018)